29 C
Vientiane
Saturday, May 24, 2025
spot_img
Home Blog Page 289

Brand & Demand: Frost & Sullivan’s Tactical Marketing Services Fuel B2B Pipeline Growth Amid Economic Volatility

Proven programs help companies stay visible, engage high-value buyers, and deliver measurable ROI – even in a downturn

LONDON, April 16, 2025 /PRNewswire/ — As global economic uncertainty continues to impact business strategies, Frost & Sullivan is spotlighting its proven suite of tactical marketing support services – designed to help companies accelerate customer acquisition, sustain market visibility, tell their story effectively, and drive measurable revenue impact, even in challenging times.

While many organisations respond to economic headwinds by cutting budgets or pausing marketing efforts, Frost & Sullivan advises a more strategic approach: lean in.

“Economic slowdowns often present the greatest opportunities for market share growth,” says Dr. Brian Cotton, Partner at Frost & Sullivan. “When competitors go quiet, forward-thinking companies can use that space to gain ground. But it requires executional excellence and strategic urgency.”

Execution Power for Your Marketing Strategy

Frost & Sullivan’s tactical marketing support services help medium and large enterprises execute high-impact marketing programs with speed, focus, and flexibility. Built on over six decades of industry expertise, the offering includes:

  • Content Marketing: Blog posts, video campaigns, infographics, interactive white papers, vBooks, and more—each tailored to help you tell your story in compelling, audience-relevant formats
  • Product Marketing & Thought Leadership: Executive briefs, webinars, and virtual think tanks that position your brand as a trusted authority and storyteller in your space
  • Account-Based Marketing (ABM): Highly targeted campaigns aligned with your ideal customer profile, designed to engage and convert decision-makers
  • Event Marketing: Executive luncheons, curated roundtables, and virtual events that deepen connections and bring your brand narrative to life in live settings

These services are tailored to amplify your existing strategy – enhancing lead generation, nurturing buyer relationships, and accelerate your sales pipeline.

The Time for Action Is Now

In today’s climate, where budgets are scrutinized and sales cycles tighten, marketing and sales alignment is critical. Frost & Sullivan helps clients move faster without sacrificing quality—by applying data-driven strategies, precise targeting, and industry insight to every campaign.

“Working with trusted partners like us means you don’t have to choose between speed and quality,” adds Dr. Cotton. “We bring deep industry knowledge, proven frameworks, and the executional firepower to help you stay ahead.”

Ready to Strengthen Your Funnel?

Don’t let economic headwinds slow your growth. The right support can make all the difference. Whether you’re looking to increase lead volume, elevate content impact, or turn prospects into customers faster, Frost & Sullivan’s tactical marketing services are designed to deliver measurable results – when it matters most.

Curious how strategic pipeline acceleration can boost your results in today’s economy?

Connect directly with brian.cotton@frost.com for an exploratory chat and discover how Frost & Sullivan can help supercharge your sales funnel.

YOUR TRANSFORMATIONAL GROWTH JOURNEY STARTS HERE. Frost & Sullivan’s Growth Pipeline Engine, transformational strategies and best-practice models drive the generation, evaluation, and implementation of powerful growth opportunities. Is your company prepared to survive and thrive through the coming transformation? Join the Journey

Editor’s Note

To arrange an interview or for any questions, please contact:

Kristina Menzefricke
Marketing & Communications
Global Customer Experience, Frost & Sullivan
kristina.menzefricke@frost.com 

 

Webull Announces Closing of Business Combination Transaction with SK Growth Opportunities Corporation

Shares are trading on Nasdaq under the ticker “BULL”

ST. PETERSBURG, Fla., April 16, 2025 /PRNewswire/ — Webull Corporation (NASDAQ: BULL) (“Webull” or the “Company”), the owner of the Webull online investment platform, and SK Growth Opportunities Corporation (“SK Growth”) (NASDAQ: SKGR), a special purpose acquisition company, today announced the closing of their previously announced business combination (the “Business Combination”). The Business Combination was approved by SK Growth shareholders on March 30, 2025. Upon closing, SK Growth became a wholly owned subsidiary of Webull, and the ordinary shares and warrants of SK Growth converted to ordinary shares and warrants of Webull. Effective with the start of trading on April 11, 2025, SK Growth was delisted and Webull ordinary shares, warrants and incentive warrants began trading on Nasdaq under the ticker symbols “BULL,” “BULLW,” and “BULLZ,” respectively. In celebration of its listing, Webull rang the Nasdaq opening bell today. 

The Webull online investment platform provides a full suite of financial products, including in-depth data and analytic tools. The Company differentiates itself from other online investment platforms and legacy investment service providers by offering retail investors in markets across the globe an intuitive user experience and extensive functionality constructed to help customers build wealth over time.

Webull launched in the United States in 2018 and has since expanded to 13 additional markets across Asia Pacific, Europe and Latin America. Today, the Webull App has been downloaded more than 50 million times and has over 23 million registered users globally.

“Becoming a publicly traded company marks a significant milestone in Webull’s history,” said Anthony Denier, Group President and US CEO of Webull. “This next step in our company’s journey will position us to serve the growing number of experienced, digitally savvy retail investors who demand a more sophisticated retail trading partner that can grow with and serve them over decades. Webull’s advanced trading and investment offerings make us the partner of choice for the next generation of retail investors looking to capitalize on the dynamic world of trading and investment. I am grateful for our team’s dedication to our customers’ financial success and our mission to create a more accessible and empowering retail investing experience.”

Advisors

Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, is acting as SK Growth’s exclusive financial advisor and lead capital markets advisor. Kirkland & Ellis LLP is acting as Webull’s U.S. legal counsel, and Wilson Sonsini Goodrich & Rosati, Professional Corporation is acting as SK Growth’s U.S. legal counsel.

About Webull 

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 23 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, and fractional shares through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at www.webullcorp.com.

Information about Webull and its securities can also be accessed through the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov, where Webull will be filing reports, including reports on Form 6-K and annual reports on Form 20-F.

Webull Investor Relations
ir@webullcorp.com

Webull Media Relations
5W Public Relations
Nicholas Koulermos
Webull@5wpr.com
(212) 999-5585

Webull Announces Closing of Business Combination Transaction with SK Growth Opportunities Corporation

Shares are trading on Nasdaq under the ticker “BULL”

ST. PETERSBURG, Fla., April 16, 2025 /PRNewswire/ — Webull Corporation (NASDAQ: BULL) (“Webull” or the “Company”), the owner of the Webull online investment platform, and SK Growth Opportunities Corporation (“SK Growth”) (NASDAQ: SKGR), a special purpose acquisition company, today announced the closing of their previously announced business combination (the “Business Combination”). The Business Combination was approved by SK Growth shareholders on March 30, 2025. Upon closing, SK Growth became a wholly owned subsidiary of Webull, and the ordinary shares and warrants of SK Growth converted to ordinary shares and warrants of Webull. Effective with the start of trading on April 11, 2025, SK Growth was delisted and Webull ordinary shares, warrants and incentive warrants began trading on Nasdaq under the ticker symbols “BULL,” “BULLW,” and “BULLZ,” respectively. In celebration of its listing, Webull rang the Nasdaq opening bell today. 

The Webull online investment platform provides a full suite of financial products, including in-depth data and analytic tools. The Company differentiates itself from other online investment platforms and legacy investment service providers by offering retail investors in markets across the globe an intuitive user experience and extensive functionality constructed to help customers build wealth over time.

Webull launched in the United States in 2018 and has since expanded to 13 additional markets across Asia Pacific, Europe and Latin America. Today, the Webull App has been downloaded more than 50 million times and has over 23 million registered users globally.

“Becoming a publicly traded company marks a significant milestone in Webull’s history,” said Anthony Denier, Group President and US CEO of Webull. “This next step in our company’s journey will position us to serve the growing number of experienced, digitally savvy retail investors who demand a more sophisticated retail trading partner that can grow with and serve them over decades. Webull’s advanced trading and investment offerings make us the partner of choice for the next generation of retail investors looking to capitalize on the dynamic world of trading and investment. I am grateful for our team’s dedication to our customers’ financial success and our mission to create a more accessible and empowering retail investing experience.”

Advisors

Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, is acting as SK Growth’s exclusive financial advisor and lead capital markets advisor. Kirkland & Ellis LLP is acting as Webull’s U.S. legal counsel, and Wilson Sonsini Goodrich & Rosati, Professional Corporation is acting as SK Growth’s U.S. legal counsel.

About Webull 

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 23 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, and fractional shares through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at www.webullcorp.com.

Information about Webull and its securities can also be accessed through the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov, where Webull will be filing reports, including reports on Form 6-K and annual reports on Form 20-F.

Webull Investor Relations
ir@webullcorp.com

Webull Media Relations
5W Public Relations
Nicholas Koulermos
Webull@5wpr.com
(212) 999-5585

WHO and WEF Are Pushing AI in Global Healthcare — What It Means for the Market

Equity Insider News Commentary

Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, April 16, 2025 /PRNewswire/ — Equity Insider News Commentary – The potential for artificial intelligence (AI) in healthcare is still unfolding, both for patients and providers. A recent report from Deloitte found that 71% of healthcare industry leaders expect improved profitability this year, and it comes with rising AI implementation in care. At a global level, the World Health Organization (WHO) recently launched a new AI collaboration center for healthcare through the Digital Ethics Center at Delft University of Technology in the Netherlands, while the World Economic Forum (WEF) is championing prioritizing investments in evidence, infrastructure, and equity. At the innovation level, the private sector is making moves, with notable AI healthcare developments coming recently from Avant Technologies, Inc. (OTCQB: AVAI), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Tevogen Bio Holdings Inc. (NASDAQ: TVGN, TVGNW), Amesite Inc. (NASDAQ: AMST), and Palantir Technologies Inc. (NASDAQ: PLTR).

The article continued: According to analysts at McKinsey who have surveyed healthcare leaders about their perspectives and approaches to generative AI (gen AI) since 2023, recently found that 85% of respondents were exploring or had adopted gen AI capabilities. Barclays expects growth in the AI healthcare market to explode at a 30% CAGR through 2030, supported by rising investment from pharma companies, hospitals, and insurers.

Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit

Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, continues to build momentum in the AI-driven healthcare sector through its joint venture with Ainnova Tech, a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI) and developers of the Vision AI platform. Today, the two companies announced that following Ainnova’s sponsorship and its CEO’s key role at the 2025 Healthcare Innovation Summit in Mexico City, both Avant and Ainnova, through their joint venture, Ai-nova Acquisition Corp. (AAC), are building on Ainnova’s strong presence in Mexico by expanding its footprint across Latin America.

Ainnova has initiated its first commercial pilots in both Chile and the Dominican Republic to work directly with prestigious hospitals that cover the full spectrum of care—from primary to highly specialized services. These pilot programs aim to demonstrate, (i) cost reduction in preventive diagnostics; (ii) increased efficiency in medical resource allocation and patient flow; (iii) enhanced institutional reputation driven by technological innovation; and (iv) improved profitability for participating healthcare centers through optimized patient referrals.

The pilot programs leverage Ainnova’s proprietary Vision AI platform to identify health risks in real time, which enable seamless referrals for specialty care or further diagnostic tests when a positive risk is detected. The broader vision for the joint venture involves deploying an automated, low-cost retinal imaging device integrated with its AI-driven platform to deliver comprehensive preventive risk screening. From just two retinal images, blood pressure and some lab test information, the system will assess risks for: cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).

The message that Ainnova’s CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.

Avant has partnered with Ainnova to form AAC so the two companies can advance and commercialize Ainnova’s technology portfolio worldwide. AAC holds the global licensing rights to the technology portfolio, including its Vision AI platform and is versatile proprietary retinal cameras and algorithms validated on more than 2.3 million clinical data points.

This also follows Ainnova’s recent strategic alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared across the Americas. Avant and Ainnova have identified Brazil and the United States as key strategic markets. Ainnova is currently addressing regulatory pathways in Brazil with the support of its MDSAP certification to meet ANVISA requirements, paving the way for rapid market entry.

Ainnova is being guided by global CRO Fortrea ahead of the important pre-submission meeting with the FDA. The goal is to seek 510(k) clearance for Vision AI in detecting diabetic retinopathy, a gateway to broader use across multiple chronic disease categories.

At the same time, Ainnova is advancing its regulatory roadmap for the U. S. The objective is to begin clinical trials in the coming months to obtain FDA approval and commercialize its technology in the U.S.—initially targeting markets where reimbursement codes for diabetic retinopathy are already approved.

Between FDA progress, high-profile alliances, and a growing international presence, Avant Technologies continues to carve out a niche in the convergence of AI, diagnostics, and preventative care. Investors looking for small-cap exposure to the healthcare AI revolution may want to keep AVAI on the radar as these developments unfold.

CONTINUED… Read this and more news for Avant Technologies at:

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/ 

Within its Q4 and FY 2024 financial results report, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) highlighted that enrollment in its pivotal SERENITY At-Home Phase 3 trial has surpassed 60%, targeting agitation associated with bipolar disorder and schizophrenia using BXCL501. Topline data is expected in the second half of 2025 to support a potential sNDA for IGALMI® label expansion.

“We believe that our SERENITY program presents an exciting opportunity to address a substantial unmet medical need — the 23 million episodes of bipolar and schizophrenia-related agitation that occur annually in the United States at home1-3 — and expand the market potential for our lead neuroscience asset BXCL501,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “We are pleased that patient enrollment in our SERENITY At-Home pivotal Phase 3 trial is progressing well and that we have recently strengthened our cash position to further advance this important study.”

The company also highlighted reduced R&D and SG&A expenses in 2024, leading to a significantly lower net loss compared to 2023. A $14 million equity raise brought its total cash position to $35 million to help fund continued development.

Tevogen Bio Holdings Inc. (NASDAQ: TVGN, TVGNW) recently announced it has engaged Databricks to accelerate development of its proprietary PredicTcell AI platform, which models immunologically active peptides and predicts T cell receptor engagement. Databricks will contribute engineering expertise and data infrastructure to support the platform’s scalability and precision.

This builds on Tevogen’s broader AI initiative, Tevogen.AI, which also includes support from Microsoft Research. The company is aiming to transform precision medicine through machine learning and advanced immunotherapy modeling.

Amesite Inc. (NASDAQ: AMST) recently announced a successful soft rollout of its NurseMagic™ caregiver platform, targeting the 1.5 million non-clinical healthcare support workers in the U.S. With this expansion, Amesite estimates a 50% increase in its enterprise addressable market.

“We are accelerating contract closures, increasing deal sizes, and expanding existing agreements with a growing suite of features,” said Brandon Owens, VP of Sales at Amesite. “Organizations that deploy our platform across their entire workforce realize a disproportionate advantage—dramatically reducing audit risk and operational costs. By delivering the right NurseMagic™ solution to every employee, we empower agencies and corporations to seamlessly scale their contracts to cover 100% of their workforce with just a few clicks.”

The company has seen contract growth with hospice providers spike by over 3,000%, alongside a 1,000% increase in average contract size. NurseMagic™, built on Amesite’s proprietary AI and HIPAA-compliant infrastructure, aims to streamline documentation and improve patient care across clinical and non-clinical staff.

Palantir Technologies Inc. (NASDAQ: PLTR) has joined forces with R1 to launch R37, a dedicated AI lab focused on revolutionizing healthcare revenue cycle management. The partnership merges Palantir’s advanced agentic AI with R1’s data-rich infrastructure, which processes over 1.2 billion workflow actions and 180 million annual payer transactions.

R1 brings unmatched ambition to an area of healthcare that desperately needs it,” said Alex Karp, co-founder and CEO of Palantir Technologies. “By embedding our engineers directly within R1’s operations, we can rapidly scale intelligent automation and drive measurable impact at speed—ultimately enabling providers to focus on delivering better patient care.”

R37 aims to automate labor-intensive tasks like coding, billing, and denials at scale, helping providers boost cash flow and reduce administrative overhead. The lab is already yielding promising results in testing, with enterprise rollouts expected in the second half of 2025.

Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/  

CONTACT:

Equity Insider
info@equity-insider.com
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

 

 

 

Milliken & Company Releases 2024 Sustainability Report

For the seventh consecutive year, company discloses detailed assessment of sustainability metrics and targets

SPARTANBURG, S.C., April 16, 2025 /PRNewswire/ — Diversified global manufacturer Milliken & Company today released its seventh annual sustainability report that discloses performance against its 2025 Sustainability Goals and 2030 net-zero targets. The report details the company’s strides across its people, product, planet, net-zero, and business conduct activities.

For the seventh consecutive year, Milliken released its sustainability report that discloses performance against its 2025 Sustainability Goals and 2030 net-zero targets.
For the seventh consecutive year, Milliken released its sustainability report that discloses performance against its 2025 Sustainability Goals and 2030 net-zero targets.

“Sustainability is at the core of Milliken’s business strategy, and our 2024 sustainability report highlights our performance, processes, and progress,” said Halsey Cook, president and CEO at Milliken. “The progress we have made would not be possible without the contributions and commitment of our associates, customers, and partners. We recognize that sustainability is a complex challenge and together, we are committed to continuous improvement in our practices.”

The 2024 Sustainability Report includes updates on each of Milliken’s key impact areas, including:

  • People: By focusing on back-to-basics priorities, Milliken reduced lost-time incidents in 2024. The company also achieved its goal of 100,000 volunteer hours a full year ahead of schedule and exceeded its original 2025 volunteer goal by an additional 31,000 hours.
  • Product: In 2024, Milliken evaluated 100% of new products using sustainability assessments—a substantial improvement from a 22% baseline reported in 2018— while also becoming the first textile manufacturer to offer non-PFAS materials for all three layers of firefighter turnout gear. In addition, Milliken’s N/XT Life™ program and partnership with The Recycling Partnership’s Center for Sustainable Behavior and Impact demonstrated the company’s support of circular economy concepts.
  • Planet: Milliken surpassed its 2025 renewable energy goal in 2022 and continues to explore solutions to expand use of renewable energy to reduce emissions. The company’s continued focus on thermal drying biosolids from wastewater treatment and the elimination of coal ash from steam generation have contributed to waste reduction. In 2024, Milliken optimized wastewater treatment processes and targeted various waste streams across its manufacturing locations, leading to a decrease in waste intensity compared to its 2018 baseline.
  • Net-Zero: Milliken’s 2024 scope 1 and 2 emissions were reduced 42% from its 2018 baseline, nearing the company’s 2030 target of a 50% reduction. Since 2018, Milliken has invested more than $35 million in coal elimination with cogeneration, energy efficiency, increased renewable electricity, and modernizing manufacturing operations. The company’s efforts to reduce scope 3 emissions include supplier engagement, improving product sustainability data, and sourcing lower-carbon materials.
  • Business Conduct: Milliken reaffirmed its commitment to the U.N. Global Compact, pledging to uphold the Ten Principles that focus on human rights, labor standards, environmental protection, and anti-corruption. The company strives to integrate these principles into daily operations and strategy and actively seeks projects that advance these broader developmental goals.

“Milliken’s 2024 Sustainability Report reflects our progress and demonstrates our commitment to our sustainability journey,” said Kasel Knight, SVP, Chief Legal Officer and head of sustainability at Milliken. “We remain committed to driving positive change and motivated by the strides we’ve made.”

Milliken’s 2024 Sustainability Report can be found at milliken.com/sustainability, alongside additional net-zero resources and prior years’ reports.

About Milliken
Milliken & Company is a global manufacturing leader whose focus on materials science delivers tomorrow’s breakthroughs today. From industry-leading molecules to sustainable innovations, Milliken creates products that enhance people’s lives and deliver solutions for its customers and communities. Drawing on thousands of patents and a portfolio with applications across the textile, flooring, chemical and healthcare businesses, the company harnesses a shared sense of integrity and excellence to positively impact the world for generations. Discover more about Milliken’s curious minds and inspired solutions at milliken.com and on Facebook, Instagram, and LinkedIn.

 

OCI GLOBAL CONFIRMS EURO EQUIVALENT DETAILS FOR Q2 2025 EXTRAORDINARY DISTRIBUTION

AMSTERDAM, April 16, 2025 /PRNewswire/ — OCI Global (Euronext: OCI) (“OCI” or the “Company”) today confirms that further to its announcement to pay an extraordinary cash distribution of USD 4.74 per share (USD 1.0 billion in total) on or around 7 May 2025, the Euro equivalent amount for those shareholders that elect for payment in EUR instead of USD will be determined using the appropriate exchange rate on 6 May 2025. The Company will make a distribution in USD unless the relevant shareholder has opted for a distribution in EUR.

About OCI Global
Learn more about OCI at www.oci-global.com. You can also follow OCI on LinkedIn.

Frost & Sullivan Recognizes Ontic with the 2025 Global Company of the Year Award for Revolutionizing Security Intelligence

Ontic’s unified platform empowers corporate security teams to manage threats, mitigate risks, and make businesses stronger.    

SAN ANTONIO, April 16, 2025 /PRNewswire/ — Frost & Sullivan recently researched the digital intelligence solutions industry and, based on its findings, recognizes Ontic with the 2025 Global Company of the Year Award. Ontic is redefining security intelligence with its always-on digital intelligence platform, empowering security teams with situational awareness, deep contextual analysis, and predictive threat detection.

Ontic’s Connected Intelligence platform transforms fragmented security operations into an integrated hub that enables proactive threat management. By centralizing critical data on principals, threats, and incidents, Ontic eliminates the blind spots that plague traditional security approaches and enables early threat detection. In today’s environment of expanded threats, sophisticated threat actors, and the critical importance of digital intelligence, Ontic provides security teams with the foundation they need to evolve from reactive responders to strategic business enablers. As an end-to-end technology solution, the platform integrates intelligence, investigative research, threat assessments, and incident and case management workflows with critical business systems, creating a continuous security intelligence cycle that anticipates threats before they materialize.

What sets Ontic apart is its ability to unify traditionally sold security functions while enhancing cross-functional collaboration across the enterprise. Advanced machine learning algorithms and robust open-source intelligence (OSINT) capabilities enable security teams to intercept threat signals, conduct comprehensive risk assessments, implement continuous monitoring, and coordinate responses—all within a single, user-friendly experience. Through intelligent automation and streamlined workflows, Ontic helps security teams achieve more with constrained resources, demonstrating measurable impact that positions security as a strategic partner to the business rather than a cost center. These groundbreaking features push the boundaries of digital intelligence solutions and position Ontic as one of the most influential players in the digital intelligence solutions industry.

“Rather than relying on more passive or reactive security processes and activities, modern security teams are striving to be more proactive in detecting security threats before they can impact critical business operations,” said Danielle VanZandt, research manager for Frost & Sullivan’s security business unit.

Ontic’s leadership in the digital intelligence market is driven by its strong commitment to innovation, customer-centric approach to development, and flawless platform interoperability. The company recently introduced enhanced incident response capabilities, improved event reporting, and expanded case management functionality, delivering deeper insights and faster decision-making capabilities. Furthermore, its alliance with International SOS to jointly develop enhanced travel risk management and workforce event management solutions further solidify Ontic’s role as a market leader.

“With such a customer-centric approach underpinning its growth strategy, Ontic’s continued industry leadership remains impressive in the face of high organic growth within the digital intelligence solutions market and an array of new vendors,” noted VanZandt.

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

“We’re honored to receive Frost & Sullivan’s 2025 Best Practices Company of the Year award recognizing Ontic’s commitment to innovation, excellence, and client success,” said Manish Mehta, Chief Product Officer, Ontic. “Our vision is to provide the system of record that security teams worldwide need to break down silos, modernize their operations, and prove their value as a strategic imperative to their organizations.”

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Camila Tinajero
Marketing & Events Coordinator – Best Practices Recognition
camila.tinajero@frost.com

About Ontic

Ontic makes software that corporate and government security professionals use to proactively manage threats, mitigate risks, and make businesses stronger. Built by security and software professionals, the Ontic Platform connects and unifies critical data, business processes, and collaborators in one place, consolidating security intelligence and operations. Ontic serves corporate security teams across key programs, including physical safety and security, executive protection, intelligence, investigations, incident management, and GSOC.

For more information, please visit ontic.co or follow us on X or LinkedIn.

Media contact:
Kat Brooks
Senior Manager, Corporate Communications
kbrooks@ontic.co

Porton Advanced’s End-to-End CDMO Solutions Accelerates IND Approval of Tasly’s Innovative Dual-Targeting CAR-T Therapy

SUZHOU, China, April 16, 2025 /PRNewswire/ — April 12, 2025, Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, “P134 Cell Injection,” which has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).

As the exclusive CDMO partner for this program, Porton Advanced provided comprehensive process development and manufacturing services, including plasmid, lentiviral vectors and final CAR-T cell products. We successfully manufactured dozens of batches of clinical-grade investigational products for Investigator-Initiated Trials (IITs), with all batches passing quality control on the first attempt.

About GMB and Tasly’s Dual-Targeting CAR-T Therapy

Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system, characterized by high invasiveness, frequent recurrence, and poor prognosis. P134 Cell Injection is an autologous CAR-T product targeting CD44 and/or CD133. Its mechanism of action involves specifically recognizing and binding to antigen targets that are highly and mutually exclusively expressed in primary and recurrent GBM, thereby effectively activating and prolonging T-cell lifespan to eliminate tumor cells.


Porton Advanced: Accelerating Progress of Advanced Therapies

Our team’s expertise in cell therapy development and cGMP production ensured high-quality, on-time delivery, contributing to Tasly’s continued effort in bringing innovative oncology treatments to patients worldwide. Notably, the regulatory submission achieved zero deficiencies during the CDE review, demonstrating the high compliance of our quality system and production stability.

  • Plasmid Production: A robust two-step chromatography process enabled rapid delivery of engineering run and GMP batches, significantly shortening timelines and reducing costs.
  • Lentivirus Production: Utilizing our proprietary LV-SMART® lentiviral suspension platform, we achieved high batch-to batch consistency, high yield, high infectious, low residual impurities as well as 30% reduced material cost with animal components free.
  • CAR-T Production: Porton Advanced produced high-transfection-efficiency CAR-T cells meeting with all release standards, delivered over 10 IIT samples with consistent quality, which contributes to observable clinical efficacy in IIT study.

Leveraging our end-to-end CDMO platform, Porton Advanced has established a deep collaboration with Tasly. We sincerely wish Tasly success in the clinical development of CAR-T pipeline and hope it will soon bring new treatment options to patients with recurrent glioblastoma. We look forward to further strengthening our partnership to accelerate the delivery of transformative therapies to patients worldwide.

About Tasly Pharma

As an international modern Chinese medicine enterprise, Tasly Pharma. (Stock code: 600535) is committed to developing into a leading solution provider of medicine and health services with global influence in China. With “people-oriented and precise innovation”, Tasly Pharma. constantly promotes the progress of medicine and health to make every human-being can enjoy the beauty and hope of life.

Headquartered in Tianjin, China, the company has more than 20 research centers worldwide and 11 production bases throughout the country. We are committed to cracking the digital code of life medicine. Adhering to the concept of “patient-centered”, we pay close attention to the evolution of disease spectrum, and make precise innovations in major therapeutic fields such as cardio-cerebrovascular, digestion and metabolism, tumor immunity, and neuroscience, which sustain the healthy life experience of human beings.

With a rich drug combination including modern Chinese medicine, chemical medicine and biological innovation medicine, regenerative medicine and the 4-D integrated health management solutions, we can provide service of the whole health journey including health examination, early warning, prevention, diagnosis, treatment and rehabilitation and a personalized and integrated medical solutions covering the whole disease course for each patient and family so as to meet the diverse needs of the individual life, optimize life experience and improve life quality.

About Porton Advanced

Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.

Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV, etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 18 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.

Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.